Company intelligence / Profile preview

Neurvati Neurosciences

New York, New York, United Statesneurvati.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Neurvati's subsidiary GRIN Therapeutics has received FDA Orphan Drug designation for radiprodil for GRIN-related neurodevelopmental disorder. The company is on track to initiate a pivotal Phase 3 trial for radiprodil in mid-2025. Promising clinical data from the Honeycomb study in gain-of-function patients with treatment-resistant symptoms provides strong rationale for Phase 3 development[8][9].

Therapeutic areas: PsychiatryRare DiseasesNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

radiprodil

Phase 1

Indications: GRIN-related neurodevelopmental disorder, Tuberous sclerosis complex, Focal cortical dysplasia type II

Beyond the preview

Go deeper on Neurvati Neurosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurvati Neurosciences.

Explore the full profile